|If you have trouble viewing this page, click here to view the newsletter online on our website.|
April 25, 2011
MESSAGE FROM THE DIRECTOR
Case Comprehensive Cancer Center Renewal – Countdown to May 2012
We are currently in the fifth year of our six-year CCSG award. I remind you that we were awarded a sixth year based on the "Outstanding" review of our last competitive renewal application.
Over the next year all of you, as members, will participate in our efforts to renew our award. We submit our fifth competitive renewal in May 2012, which will take a full year of concerted effort on the part of our more than 300 members. We have established a timeline for this effort. Keeping to this timeline will take considerable expertise and thoughtful coordination by the program leaders and the focus area leaders for each scientific program. The core leaders and the core group cluster leaders will be working with you as well to develop strong descriptions of our core facilities emphasizing the importance that they have in your individual research programs.
The first phase (due end of May 2011) of this renewal effort will be the initial draft of the scientific programs. These will be written by the program leaders, with support of the scientific focus group leaders, and will describe the overall scope of the program, its scientific focus areas, and the scientific highlights and accomplishments of the program membership.
The second phase (due June 2011) will be the descriptions of the shared resources of the Cancer Center and their use by Cancer Center members.
The third phase (July 2011) includes a comprehensive assessment of all the active and recent clinical trials to highlight both the scientific goals of these trials and the accrual that we have made to these clinical investigations. Most important will be our focus on investigator-initiated clinical trials, and clinical trials that emerge from our scientific programs and have laboratory correlative efforts within our scientific program areas.
At each point along the way, we will have extensive internal and external reviews. We will rely on our institutional internal advisory board, program leaders, and senior leaders to review the program and shared resource written descriptions, and we will review progress at our retreat in July.
As we move into the third draft of our programs in the fall of 2011, we will have formal external reviews of each of the scientific programs based on the written program descriptions. This very important review phase provides the most precise and concentrated review effort of the reapplication process. This extensive effort beforehand is to make sure we have provided the best descriptions of our programs by the time they go for external review. In my experience, this may well ensure that each of our programs scores in the outstanding to exceptional range.
As I noted, each of you will play an important role as you interact within your program and with program leaders to describe the exceptional work you have been doing. I look forward to your involvement and your feedback during this most important renewal year.
Thank you for your support and ongoing commitment to the Case Comprehensive Cancer Center.
Stan Gerson, MD
CCSG Renewal Timeline
CASE CCC IN THE NEWS
Middle-Aging and Cancer
MARK YOUR CALENDARS
Cancer Center Seminar Series: Dissecting the Paths of Ovarian Cancer Development and Chemotherapy Resistance
Friday, April 29
Please join us Friday, April 29 at the next Cancer Center Seminar Series featuring Analisa DiFeo, PhD. Dr. DiFeo, Instructor of Genetics and Genomic Sciences at the Mount Sinai School of Medicine, will present Dissecting the Paths of Ovarian Cancer Development and Chemotherapy Resistance.
Dr. Analisa DiFeo is an Instructor in the Department of Genetics and Genomic Sciences at Mount Sinai School of Medicine in New York. Her initial research studies were focused on uncovering the role of the KLF6 tumor suppressor gene in ovarian cancer. She played a central role in defining KLF6 and its novel oncogenic splice variant, KLF6-SV1, as a key regulator of a number of human malignancies, but mainly focused on epithelial ovarian cancer (EOC). Her findings were the first to demonstrate that a majority of ovarian cancer tumors have increased expression of the oncogenic KLF6-SV1 isoform, and that this variant is a novel anti-apoptotic protein which regulates chemotherapy response.
Currently, Dr. DiFeo's laboratory os working toward better understanding the mechanism by which small noncoding RNAs (microRNAs) are involved in ovarian tumor biology and the development of chemoresistance. Work in her laboratory is focused on microRNAs that may serve both as potential predictive markers for individualized therapy and novel therapeutic targets.
Dr. DiFeo has received numerous awards, including the Liz Tilberis Scholar Award from the Ovarian Cancer Research Fund, the AstraZeneca Scholar-in-Training Award from the American Association of Cancer Research, and the Doctoral Dissertation Award from Mount Sinai School of Medicine.
Case CCC Annual Scientific Retreat
The Case CCC Annual Scientific Retreat will be July 8-9 at Corporate College East. Details will be posted soon.
Damon Runyon Cancer Research Foundation
The Damon Runyon Cancer Research Foundation is accepting applications for the following funding opportunities:
The Damon Runyon Fellowship Award is the Foundation's oldest and most well recognized award. It is one of the highest accolades an early career scientist can receive. The grant is designed to give the nation's top minds the resources to further hone their cancer research skills and explore their own innovative ideas, while working with mentors in top universities and cancer research centers. Candidates must apply for the fellowship under the guidance of a Sponsor-a scientist (tenured, tenure-track or equivalent position) capable of providing mentorship to the Fellow. Only one fellowship application will be accepted from a Sponsor or Fellow per review session; there is no limit, however, to the number of applications from an institution.
Application Deadline: August 15
The Damon Runyon-Rachleff Innovation Award funds cancer research by exceptionally creative thinkers with "high-risk/high-reward" ideas- ideas that have the potential to significantly impact cancer, but lack sufficient preliminary data to obtain traditional funding. Institutional nominations are not required and there is no limit to the number of applications that can be received from a particular institution.
Pre-Proposals Deadline: June 1
DOD CDMRP Breast Cancer Research Program (BCRP)
Applications are now being accepted for the following funding opportunities from the Breast Cancer Research Program (BCRP):
Postdoctoral Fellowship Award
Era of Hope Scholar Award
Transformative Vision Award
DOD CDMRP Prostate Cancer Research Program (PCRP)
Applications are now being accepted for the following funding opportunities from the Prostate Cancer Research Program (PCRP):
Collaborative Undergraduate HBCU Student Summer Training Program Award
Exploration: Hypothesis Development Award
Health Disparity Research Award
Health Disparity Training Award
Physician Research Training Award
Population-Based Research Award
Postdoctoral Training Award
Idea Development Award
Synergistic Idea Development Award
Pilot Project Grants: American Cancer Society IRG Awards
The Case CCC is currently accepting applications for American Cancer Society Institutional Research Grant (IRG) awards. Pilot funding is available for projects in basic, clinical, prevention and control, behavioral, health services, and epidemiology cancer research with awards up to $30,000 for one-year cancer research projects that provide the basis for future independent grants.
Instructions, frequently asked questions, and application forms are available at http://cancer.case.edu. Contact Terri Daso, Cancer Center Administration (844-7252, firstname.lastname@example.org) for more information.
LOI Deadline: June 13
Message from Dr. David Wald, Scientific Director, Hematopoietic Stem Cell Core Facility
We appreciate your participation!
**All events are open to anyone interested in attending
Pathology Research Seminar
Physiology and Biophysics Seminar
Cancer Biology Invited Speaker Seminar
Stem Cell Biology and Regenerative Medicine
Hematology and Oncology Division Research Conference
Cellular and Molecular Biology of Disease Symposium Series
Immunology Invited Speaker Seminar Series
Cellular and Molecular Biology of Disease Symposium Series
Taussig Cancer Institute Grand Rounds canceled
Cell Biology Seminar
Pathology Graduate Student Defense Seminar
Cancer Center Seminar Series
Cancer Center Research in Progress Seminar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
Breast Cancer Detection and Management: Issues for 2011
Case CCC Annual Scientific Retreat
ADDITIONAL UPCOMING SEMINARS & EVENTS
2011 Clinical and Translational Research and Education Meeting: ACRT/SCTS Joint Annual Meeting
Cincinnati Cancer Symposium Series: 2011 Symposium on NF-κB, Cancer, Obesity, and Inflammation
4th International Symposium on Cancer Metastasis and the Lymphovascular System
2nd Annual Department of Medicine Research Day
Race for the Place
International Society for Stem Cell Research (ISSCR) Annual Meeting
Cancer Health Disparities Summit 2011
8th International Conference of the Society for Integrative Oncology: Innovating Integrative Oncology: New Science, New Solutions
PREVIOUSLY ANNOUNCED FUNDING OPPORTUNITIES
Avon Foundation Breast Cancer Research Program
Translational Technology Concept Studies of Circulating Tumor and Endothelial Cells (CTC/CEC)
NIH BULLETIN – Notices and Funding Opportunities
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!
Send items to email@example.com.